



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/216031/>

Version: Accepted Version

Article:

Mortensen, H.R., Populaire, P., Hoffmann, L. et al. (2024) Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer. *Radiotherapy and Oncology*, 190. 109980. ISSN: 0167-8140

<https://doi.org/10.1016/j.radonc.2023.109980>

© 2023, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648

A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer

Mortensen HR^{*1}, Populaire P^{*2, 12}, Hoffmann L^{3,9}, Moeller DS^{3,9}, Appelt A⁴, Nafteux P⁵, Muijs CT⁶, Grau C¹, Hawkins M⁷, Troost E⁸, Defraene G¹², Canters R¹¹, Clarke C¹³, Weber DC¹¹, Korevaar EW⁶, Haustermans K^{#2, 12}, Nordsmark M^{#3}.

The PROTECT consortium; Val Gebski, Achiam MP¹⁴, Sheraz Marker, Ganesh Radhakrishna, Maaïke Berbee, Daniele Scartoni, Esther Orlandi, Jerome Doyen, Vincent Gregoire, Gilles Crehange, Johannes Langendijk, Paula Lorgelly, Hedwig Blommenstein, Camilla S Byskov, Mai L Ehmsen, Maria Fuglsang Jensen, Gloria Vilches Freixas, Rebecca Bütoft.

1 Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark

2 University Hospitals Leuven, Department of Radiation Oncology, Belgium

3 Department of Oncology and Medical physics, Aarhus University Hospital, Aarhus, Denmark

4 University of Leeds, Leeds, UK

5 University Hospitals Leuven, Department of Thoracic Surgery, Belgium

6 Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

7 University College Hospital NHS Foundation Trust, London, UK

8 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden; OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, and Helmholtz-Zentrum Dresden-Rossendorf; Institute of Radiooncology – OncoRay Helmholtz-Zentrum Dresden-Rossendorf, Germany;

9 Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark

10 Department of Radiation Oncology (Maastr), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, The Netherlands.

11 Center for Proton Therapy, Paul Scherrer Institut, Villigen, Switzerland; Radiation Oncology Department, University Hospital Zurich, Zurich, Switzerland.

12 KU Leuven– University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium

13 Health Economics Analysis and Research methods Team (HEART), UCL Research Dept. of Primary Care and Population Health, London, UK

14 Dept. Surgery and Transplantation, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

* shared first-authorship # shared last authorship

Background

For patients diagnosed with locally advanced esophageal (EC) and gastroesophageal junction (EGC) cancers neo-adjuvant chemoradiotherapy (nCRT) followed by surgical resection [1] and adjuvant immunotherapy is considered standard of care [2]. These treatments often result in severe, acute, and late, heart- and lung complications [3–7] which can be lethal [8]. Proton therapy (PT), in comparison with photon therapy (XT), allows for dose reductions to organs at risk (OAR) such as the heart and lungs due to the finite range of protons. This may result in fewer side effects [7], shortened postoperative hospitalization, improved quality of life (QoL) [9,10] and survival benefits.

A previous randomized phase II trial by Lin et al. [7] including 145 patients undergoing either tri-modality treatment (48 %) or definitive radio-chemotherapy (52 %), showed a significant reduction in the total toxicity burden (TTB) and a postoperative toxicity score in patients treated with PT compared to XT. Noteworthy, no significant difference in neither survival nor QoL was observed. Overall survival as endpoint was not met due to challenges in recruitment caused by widespread insurance denial, the mix of patients who did or did not undergo surgery, and the small sample size. A further North-American multicenter randomized phase 3 NRG-GI006 trial (NCT03801876), comparing patients treated with PT versus intensity-modulated photon therapy (IMRT), using overall survival and grade 3 +cardiopulmonary toxicity as the primary endpoints, will randomize a total of 300 patients.

In parallel, the European PROTECT trial (NCT050555648) has been planned and opened, comparing neoadjuvant chemo-radiotherapy with either proton therapy (nCPT) or photon therapy (nCXT) combined with standard concomitant chemotherapy followed by surgery. The aim was to examine if PT based radiation dose reductions to critical OARs in the thorax, would result in lower rates of subsequent lung- and heart complications [11].

Study design

PROTECT is an unblinded randomized phase III study for patients with operable EC or EGC receiving nCXT (standard of care) or nCPT (intervention). The radiation dose is either 41.4 Gy in 23 fractions, five fractions per week or 50.4 Gy in 28 fractions, five fractions per week delivered concurrently with weekly carboplatin (AUC 2), and paclitaxel (50 mg/m²), five cycles in total.

Patients will be randomized (1:1) to either nCXT or nCPT (see Fig. 1). Stratification for histopathology (adenocarcinoma versus squamous cell carcinoma), planned surgical technique (open versus minimal invasive/robotic or hybrid) and site (proton center and collaborating photon centers) will be performed. Each proton center and collaborating photon centers will declare a standard treatment dose of either 50.4 Gy or 41.4 Gy and hence, stratification for site will reflect total radiotherapy dose as well.

All patients will receive standard diagnostic work-up including esophagogastroduodenoscopy with biopsies, UICC TNM clinical staging 8th edition [12], diagnostic FDG-PET scan, and baseline lung and heart function tests. Patients will be seen weekly during radiotherapy, every second week after nCRT until surgery as well as post-operatively (up to three months), and at eight specified time points for 5 years of follow-up.




Figure 1: PROTECT study design.

Statistical considerations

The primary endpoint is pulmonary complications within 90 days after completed surgery or radiotherapy for patients not undergoing surgery. Secondary endpoints include compliance with tri-modality treatment, other toxicities, concordance of observed pulmonary and cardiac complications with predicted complications from NTCP models, pathological complete response, TTB [11], locoregional failure, disease-free survival, overall survival, health related QoL, patient reported outcomes and health economic assessments of PT and XT.

Sample size calculation is based on expected difference between nCXT and nCPT assessed via dual dose planning performed on 22 representative patients with an assumption of a ten percent reduction in pulmonary complication rate with nCPT (10 % expected) compared to nCXT (20 % expected), (80 % power and two-sided type 1 error rate of 5 %) leading to a total number of 396 patients (198 receiving XT and 198 PT).

Quality Assurance (QA) programs

Collaboration between centers in the PROTECT consortium will ensure that tri-modality treatment is optimally delivered. This set-up will allow for firm conclusions and for early translation of the study results into clinical practice.

Radiotherapy guidelines are described in detail in the PROTECT RTQA guideline including target definition and delineation, radiation dose constraints to normal tissue, tolerances for daily image guidance, as well as treatment planning, robustness evaluation, and weekly 4DCT-based verification and adaptation. Completed and accepted pre-trial target delineation [13] and planning of benchmark cases [14], individual case reviews and site visits are mandatory prior to trial initiation. Delineations and plans of study patients are reviewed by the RTQA group.

Surgery follows the PROTECT surgery QA guideline and will be performed by surgeons specialized in upper gastrointestinal cancer with the main goal of achieving a complete resection of the tumor (R0-resection). This includes rules for surgery techniques, and documentation of individual surgery performance prior to trial initiation and during treatment with the purpose of ensuring high-quality surgery and validation of the scoring of the primary endpoint.

Patient involvement, health economics, and translational research

The PROTECT consortium is based on a collaboration between leading European proton therapy centers, their collaborating photon departments, and academic collaborators from eight European countries (Denmark, Germany, The Netherlands, Belgium, Switzerland, Italy, France, United Kingdom). The consortium is committed to strong partnerships with patients, patient organizations, and scientific networks.

Patient involvement and engagement has informed the design and content of the patient-facing material, trial recruitment and will inform dissemination activities. A key element of the PROTECT trial is the collection of patient-reported outcomes [15–17], in addition to clinical endpoints. Patient representatives have also helped inform an in-depth questionnaire on healthcare resource use, in order for health economic analyses to be undertaken. A within trial economic evaluation will estimate incremental cost effectiveness ratios, for cost per QALY gained, cost per complication avoided, and cost per TTB avoided thereby offering evidence for decision makers on the cost-effectiveness of proton therapy. To maximize the impact of the trial a platform for translational research has been created. This includes novel NTCP models, LET calculations and collection of research blood samples (e.g., for circulating tumor DNA). Results from the PROTECT randomized trial will be combined with results from the Model-based Approach (MBA) [18] in the Netherlands to validate a novel MBA approach against the conventionally accepted high-level evidence from a randomized trial.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hanna Rahbek Mortensen is Co-chair of Patient Involvement Work Package in PROTECT.

Acknowledgement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 101008134. The JU receives support from the European Union's Horizon 2020 research and innovation program and EFPIA and IBA and "Varian-a Siemens Healthineer company." The project has received funding from Novo Nordisk Foundation grant No NNF19OC0057405, Denmark. This research project is also funded by Kom op tegen Kanker (Stand up to Cancer), and the Flemish cancer society (Belgium). None of the above have any influence on study design, execution or interpretation of study results.

References

- [1] Eyck BM, van Hagen P, van der Gaast A, et al. Ten-Year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. *J Clin Oncol*. 2021;39:1995–2004.
- [2] Kelly RJ, Ajani JA, Moehler M, et al. Adjuvant Nivolumab in resected esophageal or gastroesophageal junction cancer. *N Engl J Med* 2021;384:1191–203.
- [3] Bosch DJ, Muijs CT, Mul VE, et al. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. *Ann Surg Oncol* 2014;21:605–11.
- [4] Routman DM, Garant A, Lester SC, et al. A Comparison of Grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer. *Adv Radiat Oncol* 2019;4:63–9.
- [5] Shiraishi Y, Fang P, Xu C, Song J, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. *Radiother Oncol* 2018;128:154–60.
- [6] Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. *Int J Radiat Oncol Biol Phys* 2013;86:885–91.
- [7] Lin SH, Merrell KW, Shen J, et al. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. *Radiother Oncol* 2017;123:376–81.
- [8] Lin SH, Zhang N, Godby J, et al. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. *Cancer* 2016;122:917–28.
- [9] Haj MN, De Rooij S, Hulshof M, et al. Activities of daily living and quality of life during treatment with neoadjuvant chemoradiotherapy and after surgery in patients with esophageal cancer. *J Surg Oncol* 2016;114:684–90.
- [10] Hurmuzlu M, Aarstad HJ, Aarstad AK, et al. Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. *Dis Esophagus* 2011;24:39–47.
- [11] Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2012;84:1078–85.
- [12] Rice TW, Patil DT, Blackstone E. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. *Ann Cardiothorac Surg*. 2017;6:119–30.
- [13] Thomas M, Mortensen HR, Hoffmann L, et al. Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. *Radiother Oncol* 2021;156:102–12.

- [14] Hoffmann L, Mortensen H, Møller DS, et al. Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: results from eight European centres. *Radiother Oncol* 2022;172:32–41.
- [15] Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365–76.
- [16] Blazeby JM, Alderson D, Winstone K, Steyn R, Hammerlid E, Arraras J, Farndon JR. Development of a EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. *Eur J Cancer* 1996;32A:1912–7.
- [17] Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of eq-5d (eq-5d-5l). *Qual life res* 2011;20:1727–36.
- [18] Langendijk JA, Lambin P, De Ruyscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. *Radiother Oncol* 2013;107:267–73.